Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ZTS logo ZTS
Upturn stock ratingUpturn stock rating
ZTS logo

Zoetis Inc (ZTS)

Upturn stock ratingUpturn stock rating
$153.06
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: ZTS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

19 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $190.62

1 Year Target Price $190.62

Analysts Price Target For last 52 week
$190.62 Target price
52w Low $138.76
Current$153.06
52w High $197.91

Analysis of Past Performance

Type Stock
Historic Profit -14.17%
Avg. Invested days 49
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 67.83B USD
Price to earnings Ratio 26.34
1Y Target Price 190.62
Price to earnings Ratio 26.34
1Y Target Price 190.62
Volume (30-day avg) 19
Beta 0.88
52 Weeks Range 138.76 - 197.91
Updated Date 08/14/2025
52 Weeks Range 138.76 - 197.91
Updated Date 08/14/2025
Dividends yield (FY) 1.22%
Basic EPS (TTM) 5.81

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-05
When -
Estimate 1.62
Actual 1.76

Profitability

Profit Margin 27.83%
Operating Margin (TTM) 40.2%

Management Effectiveness

Return on Assets (TTM) 15.37%
Return on Equity (TTM) 52.77%

Valuation

Trailing PE 26.34
Forward PE 24.45
Enterprise Value 72914888471
Price to Sales(TTM) 7.23
Enterprise Value 72914888471
Price to Sales(TTM) 7.23
Enterprise Value to Revenue 7.77
Enterprise Value to EBITDA 18.14
Shares Outstanding 443183008
Shares Floating 442368014
Shares Outstanding 443183008
Shares Floating 442368014
Percent Insiders 0.09
Percent Institutions 97.26

ai summary icon Upturn AI SWOT

Zoetis Inc

stock logo

Company Overview

overview logo History and Background

Zoetis Inc. was founded in 1952 as the animal health division of Pfizer. In 2013, it was spun off as an independent publicly traded company. It has grown through acquisitions and organic growth to become the world's largest producer of medicine and vaccinations for pets and livestock.

business area logo Core Business Areas

  • Livestock: Develops, manufactures and commercializes a variety of products for livestock, including cattle, swine, poultry and fish, used to prevent and treat disease and enhance animal health and productivity.
  • Companion Animal: Develops, manufactures and commercializes a variety of products for companion animals, including dogs, cats and horses, used to prevent and treat disease and enhance animal health and quality of life.

leadership logo Leadership and Structure

Kristin Peck is the CEO of Zoetis. The company has a board of directors and is structured into different business units based on species and geography.

Top Products and Market Share

overview logo Key Offerings

  • Simparica Trio: A parasiticide for dogs that protects against heartworm disease, fleas and ticks, and roundworms and hookworms. It has a significant market share in the companion animal parasiticides market. Competitors include Bravecto (Merck) and NexGard (Boehringer Ingelheim).
  • Draxxin: An injectable antibiotic used to treat bovine respiratory disease (BRD) in cattle. It is a leading product in the livestock segment. Competitors include Baytril (Bayer) and Micotil (Elanco).
  • Cytopoint: An injectable monoclonal antibody therapy for allergic dermatitis in dogs. Cytopoint is a blockbuster product driving significant revenue. Competitors are Apoquel (Zoetis) and Atopica (Elanco).

Market Dynamics

industry overview logo Industry Overview

The animal health industry is growing due to increasing pet ownership, rising demand for animal protein, and growing awareness of animal health and welfare. This results in increased spending on animal medication. Consolidation is occurring and global demand is rising.

Positioning

Zoetis is the largest animal health company globally, holding a leading position in both livestock and companion animal segments. The company's competitive advantages include its broad product portfolio, global presence, strong R&D capabilities, and established relationships with veterinarians and livestock producers.

Total Addressable Market (TAM)

The global animal health market is estimated to be over $50 billion. Zoetis is positioned to capture a substantial share of this TAM through its diverse product offerings and global reach.

Upturn SWOT Analysis

Strengths

  • Global market leader
  • Broad product portfolio
  • Strong R&D capabilities
  • Established distribution network
  • Strong brand reputation

Weaknesses

  • Dependence on acquisitions for growth
  • Exposure to currency fluctuations
  • Regulatory risks
  • Pricing pressure in some markets

Opportunities

  • Expanding into emerging markets
  • Developing innovative products and services
  • Leveraging digital technologies
  • Acquiring smaller animal health companies

Threats

  • Increasing competition
  • Generic erosion of key products
  • Economic downturns
  • Changing consumer preferences

Competitors and Market Share

competitor logo Key Competitors

  • ELAN
  • MRK
  • BMY

Competitive Landscape

Zoetis has a competitive advantage due to its size, scale, and diversified product portfolio. However, it faces competition from other major animal health companies like Elanco, Merck and Boehringer Ingelheim.

Major Acquisitions

Jurox

  • Year: 2022
  • Acquisition Price (USD millions): 506
  • Strategic Rationale: Expanded Zoetis' presence in the companion animal and livestock markets, particularly in Australia, New Zealand, and Canada.

Basepaws

  • Year: 2022
  • Acquisition Price (USD millions):
  • Strategic Rationale: Basepaws is a pet genetics company focused on microbiome, genetics and nutritional testing. This acquisition enables Zoetis to expand its portfolio into precision animal health.

Growth Trajectory and Initiatives

Historical Growth: Zoetis has demonstrated consistent revenue and earnings growth over the past several years, driven by organic growth and strategic acquisitions.

Future Projections: Analysts project continued growth for Zoetis, driven by increasing demand for animal health products and the company's strong market position.

Recent Initiatives: Recent strategic initiatives include expanding into new markets, developing innovative products, and investing in digital technologies.

Summary

Zoetis is a strong company due to its global market leadership and product offerings. They are growing and producing value for shareholders. The competitive nature of the market will test the company in the future, however, as they will face price pressure. Currency fluctuations and regulatory risks may also pose a future threat to Zoetis.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Zoetis Investor Relations
  • SEC Filings (10-K, 10-Q)
  • Industry Reports
  • Financial News Articles

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Zoetis Inc

Exchange NYSE
Headquaters Parsippany, NJ, United States
IPO Launch date 2013-02-01
CEO & Director Ms. Kristin C. Peck
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 13800
Full time employees 13800

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.